IMVT

38.79

1.70% 0.65

Dopo l'orario di chiusura: 38.57 -0.22 -0.57%

Immunovant Inc (IMVT)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché IMVT Giù? Forum Previsione

Precedente Chiudi:

$38.14

Aprire:

$38.48

Volume 24 ore:

1.05M

Relative Volume:

0.55

Capitalizzazione di mercato:

$7.96B

Reddito:

Utile/perdita netta:

$-505.61M

Rapporto P/E:

-14.01

EPS:

-2.7697

Flusso di cassa netto:

$-407.32M

1 W Prestazione:

+1.44%

1M Prestazione:

+25.45%

6M Prestazione:

+49.71%

1 anno Prestazione:

+130.76%

Intervallo 1D:

$37.75

$38.85

Intervallo di 1 settimana:

$37.51

$39.28

Portata 52W:

$14.32

$39.28

Immunovant Inc Stock (IMVT) Company Profile

Nome

Immunovant Inc

Settore

Healthcare (1098)

Industria

Biotechnology (615)

Telefono

917-410-3120

Indirizzo

1000 PARK FORTY PLAZA, DURHAM, NY

Dipendente

315

Cinguettio

Prossima data di guadagno

2026-08-10

Ultimi documenti SEC

IMVT's Discussions on Twitter

Compare IMVT vs VRTX, REGN, ARGX, ALNY, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
IMVT Immunovant Inc	38.79	7.91B	0	-505.61M	-407.32M	-2.7697
VRTX Vertex Pharmaceuticals Inc	528.04	126.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	654.27	65.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	939.68	57.70B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	312.78	40.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	189.24	39.82B	742.00K	-1.37B	-1.07B	-7.0731

Immunovant Inc Stock (IMVT) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-03-20	Iniziato	Bernstein	Mkt Perform
2026-01-06	Aggiornamento	Wolfe Research	Peer Perform → Outperform
2025-10-14	Iniziato	Truist	Hold
2025-07-10	Ripresa	Goldman	Neutral
2025-03-03	Iniziato	Jefferies	Hold
2025-01-03	Downgrade	Wolfe Research	Outperform → Peer Perform
2024-10-10	Ripresa	Raymond James	Outperform
2024-10-09	Reiterato	Oppenheimer	Outperform
2024-03-28	Iniziato	Oppenheimer	Outperform
2024-03-13	Iniziato	Goldman	Buy
2024-02-20	Iniziato	JP Morgan	Overweight
2024-02-15	Iniziato	Wolfe Research	Outperform
2023-12-12	Iniziato	Deutsche Bank	Buy
2023-10-13	Aggiornamento	UBS	Neutral → Buy
2023-09-26	Aggiornamento	Raymond James	Mkt Perform → Outperform
2023-05-01	Iniziato	BofA Securities	Buy
2023-04-25	Iniziato	Citigroup	Buy
2023-03-31	Iniziato	Piper Sandler	Overweight
2023-03-30	Iniziato	Stifel	Buy
2023-02-15	Iniziato	Cantor Fitzgerald	Overweight
2023-02-13	Aggiornamento	Guggenheim	Neutral → Buy
2023-01-03	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2022-09-26	Downgrade	UBS	Buy → Neutral
2021-12-08	Iniziato	Wells Fargo	Equal Weight
2021-08-03	Downgrade	Robert W. Baird	Outperform → Neutral
2021-08-02	Downgrade	Credit Suisse	Neutral → Underperform
2021-06-01	Downgrade	Guggenheim	Buy → Neutral
2021-06-01	Downgrade	Stifel	Buy → Hold
2020-10-28	Iniziato	UBS	Buy
2020-10-12	Iniziato	Guggenheim	Buy
2020-10-08	Iniziato	Stifel	Buy
2020-10-02	Iniziato	Credit Suisse	Outperform
2020-08-26	Reiterato	H.C. Wainwright	Buy
2020-08-25	Iniziato	Raymond James	Outperform
2020-07-29	Iniziato	H.C. Wainwright	Buy
2020-02-24	Iniziato	SVB Leerink	Outperform

Mostra tutto

Immunovant Inc Borsa (IMVT) Ultime notizie

Jun 29, 2026

Immunovant Insider Sold Shares Worth $1,532,309, According to a Recent SEC Filing - Moomoo

Jun 29, 2026

Jun 27, 2026

Immunovant COO Melanie Gloria sells $678k in company stock By Investing.com - Investing.com India

Jun 27, 2026

Immunovant CTO Jay Stout sells $1.53m in company stock By Investing.com - Investing.com Australia

Jun 26, 2026

Immunovant CFO Tiago Girao sells $384,600 in company stock By Investing.com - Investing.com Australia

Jun 26, 2026

Immunovant chief legal officer sells $682,886 in stock - Investing.com

Jun 26, 2026

Immunovant (IMVT) CFO exercises options, sells 10,000 shares at ~$38 average - Stock Titan

Jun 26, 2026

Immunovant chief legal officer sells $682,886 in stock By Investing.com - Investing.com South Africa

Jun 26, 2026

Immunovant director Atul Pande sells $57,015 in stock By Investing.com - Investing.com Canada

Jun 26, 2026

Immunovant (IMVT) COO sells 17,714 shares, keeps 224,393 stake - Stock Titan

Jun 26, 2026

Immunovant (IMVT) CTO Jay S. Stout sells 40,000 shares in open-market trades - Stock Titan

Jun 26, 2026

Immunovant (IMVT) Chief Legal Officer sells 17,824 shares after option exercise - Stock Titan

Jun 26, 2026

Immunovant (IMVT) director sells 1,500 shares after option exercise - Stock Titan

Jun 26, 2026

Insider Sale: President & Immunovant CEO of $ROIV Sells 46,234 Shares - Quiver Quantitative

Jun 26, 2026

IMVT (NASDAQ) Form 144 lists multiple vested restricted stock blocks, 40,000 header - Stock Titan

Jun 26, 2026

IMVT (NASDAQ: IMVT) files Form 144 for 17,824-share sale after option exercise - Stock Titan

Jun 26, 2026

[144] Immunovant, Inc. SEC Filing - Stock Titan

Jun 26, 2026

Immunovant Inc Actuals & Estimates (NASDAQ:IMVT) - TradingView

Jun 26, 2026

Price to book forward of Immunovant, Inc. – NASDAQ:IMVT - TradingView

Jun 26, 2026

Price to sales forward of Immunovant, Inc. – NASDAQ:IMVT - TradingView

Jun 26, 2026

Enterprise value to EBITDA forward of Immunovant, Inc. – NASDAQ:IMVT - TradingView

Jun 26, 2026

IMVT Forecast — Price Target — Prediction for 2027 - TradingView

Jun 26, 2026

Jun 25, 2026

Immunovant (IMVT) up 3.6% since last earnings report: Can it continue? - MSN

Jun 25, 2026

Jun 22, 2026

Immunovant (IMVT) CLO mandated share sale to cover RSU tax withholding - Stock Titan

Jun 22, 2026

Immunovant stock hits 52-week high at 36.39 USD By Investing.com - Investing.com Australia

Jun 22, 2026

Cutaneous Lupus Erythematosus Market to Expand at a CAGR of 8% During the Forecast Period (2026–2036) Amid Emerging Therapies and Increasing Healthcare Investments | DelveInsight - GlobeNewswire Inc.

Jun 22, 2026

Immunovant stock hits 52-week high at 36.39 USD - Investing.com

Jun 22, 2026

Jun 20, 2026

Immunovant Stockweekly view after recent volatility - Ad-hoc-news.de

Jun 20, 2026

Immunovant stock gains 12.4% in a month: What's driving it? - MSN

Jun 20, 2026

Jun 19, 2026

Immunovant (IMVT) Up 3.6% Since Last Earnings Report: Can It Continue? - Yahoo Finance

Jun 19, 2026

Jun 18, 2026